Drugs / EFG816
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03529084 | Jul 2018 → Aug 2020 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EFG816 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03529084 ↗ |
| Route | Oral | “It will be administered orally daily.” NCT03529084 ↗ |